Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vaxcyte, Inc. (PCVX)

Vaxcyte Q3 2026 net loss widens to $297.1 million from $212.8 million

Negative Impact 3 of 5 earnings Written later

Vaxcyte reported a third-quarter 2026 net loss of $297.1 million, or $1.99 per share, up from $212.8 million, or $1.56 per share, a year earlier, as research and development expenses rose to $270.3 million. Cash, cash equivalents and investments were $2,264.4 million at September 30, 2026, and the company says about $1.1 billion in net proceeds from October 2026 offerings is not included in that figure, bringing pro forma cash to about $3.4 billion. The release also reports positive topline data from the OPUS-1 Phase 3 trial of VAX-31 in adults, which shareholders will weigh against the higher spending.

Key points

  • Net loss was $297.1 million ($1.99 per share) for the quarter ended September 30, 2026, versus $212.8 million ($1.56 per share) a year earlier.
  • R&D expenses were $270.3 million versus $209.9 million, driven mainly by VAX-31 OPUS Phase 3 trials and manufacturing costs.
  • October 2026 offerings generated $1.15 billion in gross proceeds and about $1.1 billion in net proceeds; pro forma cash is about $3.4 billion.
  • OPUS-2 and OPUS-3 Phase 3 results are expected in the first half of 2027, with a BLA submission planned for the first half of 2028.

The filing

CompanyVaxcyte, Inc. (PCVX)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:08 PM ET
Accession number0001649094-26-000051

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.